Promising Oncology Developments and Strategic Insights Drive Buy Rating for Zai Lab

Leerink Partners analyst Jonathan Chang has reiterated their bullish stance on ZLAB stock, giving a Buy rating on June 3.

Jonathan Chang has given his Buy rating due to a combination of factors related to Zai Lab’s promising developments in their oncology pipeline. The updated Phase I data for ZL-1310, presented at the ASCO 2025 Annual Meeting, demonstrated its competitive efficacy in treating small cell lung cancer at doses below 2.0 mg/kg. This data suggests that ZL-1310 can outperform standard-of-care therapies while maintaining a manageable safety profile, which is crucial for its continued development.
Moreover, the potential for ZL-1310 to initiate a pivotal study later this year at these effective dose levels further supports the positive outlook for Zai Lab. The investor event held by Zai Lab during the ASCO meeting provided additional insights into their strategic plans, competitive positioning, and potential business opportunities, reinforcing confidence in the company’s future growth prospects. These factors collectively underpin Chang’s Buy rating for Zai Lab’s stock.

In another report released on June 3, Scotiabank also maintained a Buy rating on the stock with a $55.00 price target.

ZLAB’s price has also changed slightly for the past six months – from $29.200 to $31.190, which is a 6.82% increase.